Rafael Holdings, Inc. (RFL) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended January 31, 2026 (Fiscal Q2 2026). Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical-stage companies. The Company's primary strategic focus is the development of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1), following the March 2025 merger with Cyclo Therapeutics, which is now a wholly-owned subsidiary. The Company operates through three segments: Healthcare, Infusion Technology, and Real Estate.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Jan 31, 2026 | Six Months Ended Jan 31, 2026 | Balance Sheet (Jan 31, 2026) |
|---|---|---|---|
| Total Revenue | $211 | $451 | - |
| Net Loss (Consolidated) | $(6,327) | $(16,124) | - |
| Net Loss Attributable to RFL | $(6,417) | $(16,233) | - |
| Loss Per Share (Basic & Diluted) | $(0.13) | $(0.32) | - |
| Cash and Cash Equivalents | - | - | $37,779 |
| Total Assets | - | - | $99,315 |
| Total Liabilities | - | - | $16,057 |
| Working Capital | - | - | $30,090 |
| Operating Cash Flow (6mo) | - | $(14,329) | - |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased to $211,000 for the quarter (from $77,000 in Q2 2025) and $451,000 for the six months (from $205,000 in the prior year period). This growth is driven by new product revenue from the Cyclo subsidiary and sales from Rafael Medical Devices following FDA clearance of the VECTR System.
- Increased Operating Loss: Loss from operations widened to $(6.66) million for the quarter and $(16.80) million for the six months, compared to $(6.64) million and $(10.48) million in the prior year periods. The increase is primarily due to higher Research and Development (R&D) expenses ($4.53 million vs. $0.95 million for the quarter) associated with Cyclo's Phase 3 clinical trials.
- Elimination of Non-Operating Volatility: Unlike the prior year period, the current period does not include significant unrealized gains or losses on investments in Cyclo (which were recorded prior to the merger). In the prior six months, the Company recorded a $3.75 million unrealized loss on Cyclo investments.
- Goodwill Impairment: The prior year period included a $3.05 million goodwill impairment charge related to the Infusion Technology segment. No such impairment was recorded in the current period.
- Cash Position: Cash and cash equivalents decreased by approximately $15.0 million to $37.8 million, primarily due to operating losses and increased prepaid clinical costs.
Outlook, Risks, and Unusual Items
- Strategic Focus: Management is concentrating resources on the pivotal Phase 3 clinical trial for Trappsol® Cyclo™. Other holdings are being evaluated to ensure alignment with core assets.
- Subsequent Event - Debt Settlement: In February 2026 (post-period), the Company settled a significant creditor liability with a carrying value of approximately $3.9 million for a cash payment of $0.4 million. This is expected to result in a non-cash gain of approximately $3.5 million in the quarter ending April 30, 2026.
- Internal Control Weakness: Management identified a material weakness in internal controls at the acquired Cyclo subsidiary regarding the accrual and recognition of expenses, specifically clinical trial accruals. A remediation plan is underway to integrate Cyclo's processes into the Company's existing controls.
- Liquidity: The Company expects its cash balance of $37.8 million to be sufficient to meet obligations for at least the next 12 months.
- Related Party Transactions: Significant related party transactions include rental income from IDT Corporation and a Standby Purchase Agreement with Chairman Howard S. Jonas, who purchased unsubscribed shares in a rights offering in June 2025.
Investor Verification Checklist
- Clinical Trial Progress: Verify the status and enrollment rates of the pivotal Phase 3 trial for Trappsol® Cyclo™, as this is the primary value driver.
- Subsequent Gain Recognition: Confirm the accounting treatment and timing of the $3.5 million gain from the February 2026 creditor settlement in the upcoming Q3 2026 filing.
- Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness identified at Cyclo to ensure future financial reporting reliability.
- Cash Burn Rate: Assess the sustainability of the current cash position given the high R&D spend ($12.0 million for the six months) and lack of significant recurring revenue.
- Segment Performance: Review the continued viability of the Infusion Technology segment (Day Three) following the sale of certain assets and the prior year's goodwill impairment.